Back to Search
Start Over
Statins and neuroprotection
- Source :
- Expert Opinion on Investigational Drugs. 10:1847-1853
- Publication Year :
- 2001
- Publisher :
- Informa Healthcare, 2001.
-
Abstract
- The beneficial effect of beta-hydroxy-beta-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in primary prevention of coronary artery disease in those with hypercholesterolaemia and in secondary prevention in those with established coronary vascular disease are now well known. A growing body of evidence suggests that statins also possess important additional clinical benefits, such as stroke risk reduction. In this article we review the evidence that statins may be neuroprotective, especially in the brain parenchyma during stroke. We also review the observational data that statins may prevent the onset of dementia.
- Subjects :
- Endothelium
Pharmacology
Bioinformatics
Neuroprotection
Coronary artery disease
medicine
Animals
Humans
Dementia
Pharmacology (medical)
cardiovascular diseases
Stroke
biology
business.industry
nutritional and metabolic diseases
General Medicine
medicine.disease
Coronary vascular disease
Neuroprotective Agents
medicine.anatomical_structure
HMG-CoA reductase
biology.protein
lipids (amino acids, peptides, and proteins)
Observational study
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Subjects
Details
- ISSN :
- 17447658 and 13543784
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Investigational Drugs
- Accession number :
- edsair.doi.dedup.....b9f6ac6f63e57cfa9fd3ff1e991c7930